


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:


--1. to 3. (cancelled)--

--4. (currently amended) ~~The~~A compound of formula 1 ~~according to claim 3~~



-wherein:

A is a group selected from



X⁻ is an anion with a single negative charge;


R¹ and R² are each independently a C₁-C₄-alkyl optionally substituted with hydroxy or halogen;

R³ and R⁵ are each independently fluorine, chlorine, or bromine; and

R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen, fluorine, chlorine, or bromine.--

--5. (previously presented) The compound of formula 1 according to claim 4, wherein:

A is



--6. (currently amended) The compound of formula 1 according to claim ~~14~~4, wherein:

R¹ and R² are each methyl;

R³ and R⁵ are each fluorine; and

R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen or fluorine.--

--7. to 9. (cancelled)--

--10. (original) A pharmaceutical composition comprising a compound of formula 1 according to claim 4 and a pharmaceutically acceptable excipient and/or carrier.--

--11. (original) A pharmaceutical composition comprising a compound of formula 1 according to claim 5 and a pharmaceutically acceptable excipient and/or carrier.--

--12. (original) A pharmaceutical composition comprising a compound of formula 1 according to claim 6 and a pharmaceutically acceptable excipient and/or carrier.--

--13. to 15. (cancelled)--

--16. (original) The pharmaceutical composition according to claim 10, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.--

--17. (original) The pharmaceutical composition according to claim 11, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.--

--18. (original) The pharmaceutical composition according to claim 12, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.--

--19. to 21. (cancelled)--

--22. (currently amended) A method of treating COPD~~diseases in which anticholinergics provide a therapeutic benefit~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 4.--

--23. (currently amended) A method of treating COPD~~diseases in which anticholinergics provide a therapeutic benefit~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 5.--

--24. (currently amended) A method of treating COPD~~diseases in which anticholinergics provide a therapeutic benefit~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 6.--


--25. to 27. (cancelled)--

--28. (currently amended) A method of treating asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders~~, spasms in the gastrointestinal tract, or spasms in the urinary tract, ~~or menstrual disorders~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 4.--

--29. (currently amended) A method of treating asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders~~, spasms in the gastrointestinal tract, or spasms in the urinary tract, ~~or menstrual disorders~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 5.--


--30. (currently amended) A method of treating asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders~~, spasms in the gastrointestinal tract, or spasms in the urinary tract, ~~or menstrual disorders~~, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 6.--

--31. (currently amended) A compound of formula 4



wherein:

A is a group selected from



R¹ is a C₁-C₄-alkyl optionally substituted with hydroxy or halogen;

R³ and R⁵ are each independently fluorine, chlorine, or bromine C₁-C₄-alkyl, C₁-C₄-alkyloxy, hydroxy, CF₃, CN, NO₂, or halogen; and

R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen, fluorine, chlorine, or bromine C₁-C₄-alkyl, C₁-C₄-alkyloxy, hydroxy, CF₃, CN, NO₂, or halogen.--

--32. (currently amended) The compound of formula 4 according to claim 31, wherein:

R¹ is a group selected from the group consisting of methyl, ethyl, *n*-propyl, and isopropyl, each optionally substituted by hydroxy or fluorine;

~~R³ and R⁵ are each independently methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF₃, or NO₂; and~~

~~R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF₃, or NO₂.--~~

--33. (currently amended) The compound of formula 4 according to claim 31, wherein:

R¹ is methyl or ethyl;

~~R³ and R⁵ are each independently methyl, methyloxy, fluorine, chlorine, or bromine; and~~

~~R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.--~~

--34. (currently amended) The compound of formula 4 according to claim 33, wherein:

~~R³¹ and R⁵ are each is methyl independently fluorine, chlorine, or bromine; and~~

~~R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen, fluorine, chlorine, or bromine.--~~

--35. (previously presented) The compound of formula 4 according to claim 31, wherein:

R³ and R⁵ are each fluorine; and

R⁴, R⁶, R⁷, and R⁸ are each independently hydrogen or fluorine.--

--36. to 40. (cancelled)--